Inhibikase Therapeutics (IKT) Accounts Receivable: History & Chart

Inhibikase Therapeutics, Inc.(IKT)

Biotechnology · Wilmington, DE

$2.00-0.00 (-0.25%)

Delayed quote: Oct 6, 2026, 1:20 PM EDT

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Wilmington, DE

35 employees

www.inhibikase.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mark T. Iwicki

View full financials

Accounts Receivable

The latest quarterly A/R is $0. Accounts Receivable (A/R) represents money owed to the company by customers for goods or services delivered but not yet paid for.

Q2 FY2026 (2026-06-30).

Revenue|Accounts Payable|Inventory|Current Ratio|Balance Sheet

A/R

IKT A/R

$0.00

Reported quarterly accounts receivable; no daily interpolation. Q2 FY2026 (2026-06-30): $0.00.

Current A/R

Q2 FY2026 · 2026-06-30

QoQ Growth

N/A

Historical Data

Quarters of data available

Quarterly A/R History

Period	A/R	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$0	N/A	N/A
Q1 FY2026Period end 2026-03-31	$0	N/A	N/A
Q4 FY2025Period end 2025-12-31	$0	N/A	N/A
Q3 FY2025Period end 2025-09-30	$0	N/A	N/A
Q2 FY2025Period end 2025-06-30	$0	N/A	N/A
Q1 FY2025Period end 2025-03-31	$0	N/A	N/A
Q4 FY2024Period end 2024-12-31	$0	N/A	N/A
Q3 FY2024Period end 2024-09-30	$0	N/A	N/A
Q2 FY2024Period end 2024-06-30	$0	N/A	-100.00%
Q1 FY2024Period end 2024-03-31	$0	N/A	-100.00%
Q4 FY2023Period end 2023-12-31	$0	N/A	-100.00%
Q3 FY2023Period end 2023-09-30	$0	-100.00%	-100.00%
Q2 FY2023Period end 2023-06-30	$79.60K	+23.38%	N/A
Q1 FY2023Period end 2023-03-31	$64.52K	+61.78%	+34.49%
Q4 FY2022Period end 2022-12-31	$39.88K	+188.12%	-63.79%
Q3 FY2022Period end 2022-09-30	$13.84K	N/A	-93.64%
Q2 FY2022Period end 2022-06-30	$6.55K	-86.34%	-98.88%
Q1 FY2022Period end 2022-03-31	$47.98K	-56.44%	-85.58%
Q4 FY2021Period end 2021-12-31	$110.14K	-49.36%	N/A
Q3 FY2021Period end 2021-09-30	$217.48K	-62.92%	N/A
Q2 FY2021Period end 2021-06-30	$586.58K	+76.27%	N/A
Q1 FY2021Period end 2021-03-31	$332.77K	N/A	N/A
Q4 FY2020Period end 2020-12-31	$0	N/A	N/A
Q3 FY2020Period end 2020-09-30	$0	N/A	N/A
Q2 FY2020Period end 2020-06-30	$0	N/A	N/A
Q1 FY2020Period end 2020-03-31	$0	N/A	N/A
Q4 FY2019Period end 2019-12-31	$0	N/A	N/A
Q1 FY2019Period end 2019-03-31	$0	-100.00%	N/A
Q4 FY2018Period end 2018-12-31	$472.94K	N/A	N/A
Q1 FY2018Period end 2018-03-31	$147.25K	-18.55%	N/A
Q4 FY2017Period end 2017-12-31	$180.78K	N/A	N/A
Q1 FY2017Period end 2017-03-31	$0	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.

Data as of June 30, 2026